{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:18:19Z","timestamp":1789561099435,"version":"build-2803163510"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Universit\u00e9 Nice C\u00f4te d\u2019Azur"},{"DOI":"10.13039\/501100008765","name":"Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de Gastro-Ent\u00e9rologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008765","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006678","name":"Association Fran\u00e7aise pour l'Etude du Foie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006678","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["#ANR-19-CE14-0044-01, #ANR-21-CE14-0015-03, #ANR-22-CE14-0027-01, #ANR-22-CE14-0027-02, #ANR-23-CE14-0048-03, #ANR-24-CE18-2311-02"],"award-info":[{"award-number":["#ANR-19-CE14-0044-01, #ANR-21-CE14-0015-03, #ANR-22-CE14-0027-01, #ANR-22-CE14-0027-02, #ANR-23-CE14-0048-03, #ANR-24-CE18-2311-02"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"\"Investments for the Future\" IDEX UCAJedi","award":["#ANR-15-IDEX-01"],"award-info":[{"award-number":["#ANR-15-IDEX-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Obes Rep"],"DOI":"10.1007\/s13679-025-00646-8","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T22:18:48Z","timestamp":1750889928000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders"],"prefix":"10.1007","volume":"14","author":[{"given":"Marwin A.","family":"Farrugia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enzo","family":"Pini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolphe","family":"Anty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"646_CR1","unstructured":"World Health Organization. Obesity and overweight n.d. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight. Accessed 2025"},{"key":"646_CR2","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.pcad.2016.07.012","volume":"59","author":"P Vassallo","year":"2016","unstructured":"Vassallo P, Driver SL, Stone NJ. Metabolic Syndrome: An Evolving Clinical Construct. Prog Cardiovasc Dis. 2016;59:172\u20137. https:\/\/doi.org\/10.1016\/j.pcad.2016.07.012.","journal-title":"Prog Cardiovasc Dis"},{"key":"646_CR3","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966. https:\/\/doi.org\/10.1097\/HEP.0000000000000520.","journal-title":"Hepatology"},{"key":"646_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851\u201361. https:\/\/doi.org\/10.1016\/S2468-1253(22)00165-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"646_CR5","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","volume":"31","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2024;31:S32-50. https:\/\/doi.org\/10.3350\/cmh.2024.0431.","journal-title":"Clin Mol Hepatol"},{"key":"646_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.aohep.2020.03.001","volume":"19","author":"A Lonardo","year":"2020","unstructured":"Lonardo A, Mantovani A, Lugari S, Targher G. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. Ann Hepatol. 2020;19:359\u201366. https:\/\/doi.org\/10.1016\/j.aohep.2020.03.001.","journal-title":"Ann Hepatol"},{"key":"646_CR7","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.3390\/biomedicines9121915","volume":"9","author":"S Le Garf","year":"2021","unstructured":"Le Garf S, N\u00e8gre V, Anty R, Gual P. Metabolic fatty liver disease in children: a growing public health problem. Biomedicines. 2021;9:1915. https:\/\/doi.org\/10.3390\/biomedicines9121915.","journal-title":"Biomedicines"},{"key":"646_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","volume":"27","author":"VT Samuel","year":"2018","unstructured":"Samuel VT, Shulman GI. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases. Cell Metab. 2018;27:22\u201341. https:\/\/doi.org\/10.1016\/j.cmet.2017.08.002.","journal-title":"Cell Metab"},{"key":"646_CR9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.beem.2016.06.006","volume":"30","author":"S Lallukka","year":"2016","unstructured":"Lallukka S, Yki-J\u00e4rvinen H. Non-alcoholic fatty liver disease and risk of type 2 diabetes. Best Pract Res Clin Endocrinol Metab. 2016;30:385\u201395. https:\/\/doi.org\/10.1016\/j.beem.2016.06.006.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"646_CR10","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1056\/NEJMra0912063","volume":"363","author":"G Targher","year":"2010","unstructured":"Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341\u201350. https:\/\/doi.org\/10.1056\/NEJMra0912063.","journal-title":"N Engl J Med"},{"key":"646_CR11","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jhep.2020.10.030","volume":"74","author":"O Kucukoglu","year":"2021","unstructured":"Kucukoglu O, Sowa J-P, Mazzolini GD, Syn W-K, Canbay A. Hepatokines and adipokines in NASH-related hepatocellular carcinoma. J Hepatol. 2021;74:442\u201357. https:\/\/doi.org\/10.1016\/j.jhep.2020.10.030.","journal-title":"J Hepatol"},{"key":"646_CR12","doi-asserted-by":"publisher","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2024 May;74(3):229-63. https:\/\/doi.org\/10.3322\/caac.21834.","DOI":"10.3322\/caac.21834"},{"key":"646_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:1\u201328. https:\/\/doi.org\/10.1038\/s41572-020-00240-3.","journal-title":"Nat Rev Dis Primers"},{"key":"646_CR14","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","volume":"17","author":"Z Younossi","year":"2019","unstructured":"Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, Duseja A, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019;17:748-755.e3. https:\/\/doi.org\/10.1016\/j.cgh.2018.05.057.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"646_CR15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.cmet.2016.02.005","volume":"23","author":"F Magkos","year":"2016","unstructured":"Magkos F, Fraterrigo G, Yoshino J, Luecking C, Kirbach K, Kelly SC, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab. 2016;23:591\u2013601. https:\/\/doi.org\/10.1016\/j.cmet.2016.02.005.","journal-title":"Cell Metab"},{"key":"646_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/BF01225454","volume":"16","author":"W Creutzfeldt","year":"1979","unstructured":"Creutzfeldt W. The incretin concept today. Diabetologia. 1979;16:75\u201385. https:\/\/doi.org\/10.1007\/BF01225454.","journal-title":"Diabetologia"},{"key":"646_CR17","doi-asserted-by":"publisher","unstructured":"P\u0159\u00e1da Brichtov\u00e1 E, Krupov\u00e1 M, Bou\u0159 P, Lindo V, Gomes dos Santos A, Jackson SE. Glucagon-like peptide 1 aggregates into low-molecular-weight oligomers off-pathway to\u00a0fibrillation. Biophysical Journal 2023;122:2475\u201388. https:\/\/doi.org\/10.1016\/j.bpj.2023.04.027.","DOI":"10.1016\/j.bpj.2023.04.027"},{"key":"646_CR18","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/S1262-3636(08)73397-4","volume":"34","author":"J-F Gautier","year":"2008","unstructured":"Gautier J-F, Choukem S-P, Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab. 2008;34:S65-72. https:\/\/doi.org\/10.1016\/S1262-3636(08)73397-4.","journal-title":"Diabetes Metab"},{"key":"646_CR19","doi-asserted-by":"publisher","first-page":"1431292","DOI":"10.3389\/fendo.2024.1431292","volume":"15","author":"QK Liu","year":"2024","unstructured":"Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024;15:1431292. https:\/\/doi.org\/10.3389\/fendo.2024.1431292.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"646_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3803\/EnM.2024.1940","volume":"39","author":"JW Son","year":"2024","unstructured":"Son JW, Lim S. Glucagon-like peptide-1 based therapies: a new horizon in obesity management. Endocrinol Metab. 2024;39:206\u201321. https:\/\/doi.org\/10.3803\/EnM.2024.1940.","journal-title":"Endocrinol Metab"},{"key":"646_CR21","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s40262-018-0668-z","volume":"57","author":"S Hall","year":"2018","unstructured":"Hall S, Isaacs D, Clements JN. Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist. Clin Pharmacokinet. 2018;57:1529\u201338. https:\/\/doi.org\/10.1007\/s40262-018-0668-z.","journal-title":"Clin Pharmacokinet"},{"key":"646_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3897\/pharmacia.71.e132148","volume":"71","author":"L Petrova","year":"2024","unstructured":"Petrova L, Andreevska K, Parvova I, Petkova V. Systematic review of the efficacy and safety of GLP-1 receptor agonists in the treatment of patients with type 2 diabetes mellitus. Pharmacia. 2024;71:1\u201317. https:\/\/doi.org\/10.3897\/pharmacia.71.e132148.","journal-title":"Pharmacia"},{"key":"646_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s13300-020-00981-0","volume":"12","author":"T Min","year":"2021","unstructured":"Min T, Bain SC. The role of tirzepatide, dual gip and glp-1 receptor agonist, in the management of type 2 diabetes: the surpass clinical trials. Diabetes Ther. 2021;12:143\u201357. https:\/\/doi.org\/10.1007\/s13300-020-00981-0.","journal-title":"Diabetes Ther"},{"key":"646_CR24","doi-asserted-by":"publisher","unstructured":"Schneck K, Urva S. Population pharmacokinetics of the GIP\/GLP receptor agonist tirzepatide. CPT: Pharmacometrics & Systems Pharmacology. 2024 Mar;13(3):494-503. https:\/\/doi.org\/10.1002\/psp4.13099.","DOI":"10.1002\/psp4.13099"},{"key":"646_CR25","doi-asserted-by":"publisher","first-page":"14631","DOI":"10.3390\/ijms232314631","volume":"23","author":"I Forzano","year":"2022","unstructured":"Forzano I, Varzideh F, Avvisato R, Jankauskas SS, Mone P, Santulli G. Tirzepatide: a systematic update. Int J Mol Sci. 2022;23:14631. https:\/\/doi.org\/10.3390\/ijms232314631.","journal-title":"Int J Mol Sci"},{"key":"646_CR26","doi-asserted-by":"publisher","unstructured":"Nauck MA, D\u2018Alessio DA. Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovascular Diabetology 2022;21:169. https:\/\/doi.org\/10.1186\/s12933-022-01604-7.","DOI":"10.1186\/s12933-022-01604-7"},{"key":"646_CR27","doi-asserted-by":"publisher","first-page":"171179","DOI":"10.1016\/j.peptides.2024.171179","volume":"175","author":"AH Shilleh","year":"2024","unstructured":"Shilleh AH, Viloria K, Broichhagen J, Campbell JE, Hodson DJ. GLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells. Peptides. 2024;175:171179. https:\/\/doi.org\/10.1016\/j.peptides.2024.171179.","journal-title":"Peptides"},{"key":"646_CR28","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s00125-016-3874-y","volume":"59","author":"OM Farr","year":"2016","unstructured":"Farr OM, Sofopoulos M, Tsoukas MA, Dincer F, Thakkar B, Sahin-Efe A, et al. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Diabetologia. 2016;59:954\u201365. https:\/\/doi.org\/10.1007\/s00125-016-3874-y.","journal-title":"Diabetologia"},{"key":"646_CR29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.peptides.2018.09.002","volume":"111","author":"M Almutairi","year":"2019","unstructured":"Almutairi M, Al Batran R, Ussher JR. Glucagon-like peptide-1 receptor action in the vasculature. Peptides. 2019;111:26\u201332. https:\/\/doi.org\/10.1016\/j.peptides.2018.09.002.","journal-title":"Peptides"},{"key":"646_CR30","doi-asserted-by":"publisher","first-page":"bqab216","DOI":"10.1210\/endocr\/bqab216","volume":"163","author":"KV Grunddal","year":"2022","unstructured":"Grunddal KV, Jensen EP, \u00d8rskov C, Andersen DB, Windel\u00f8v JA, Poulsen SS, et al. Expression Profile of the GLP-1 Receptor in the Gastrointestinal Tract and Pancreas in Adult Female Mice. Endocrinology. 2022;163:bqab216. https:\/\/doi.org\/10.1210\/endocr\/bqab216.","journal-title":"Endocrinology"},{"key":"646_CR31","doi-asserted-by":"publisher","first-page":"bqaa201","DOI":"10.1210\/endocr\/bqaa201","volume":"161","author":"T Sato","year":"2020","unstructured":"Sato T, Shimizu T, Fujita H, Imai Y, Drucker DJ, Seino Y, et al. GLP-1 Receptor Signaling Differentially Modifies the Outcomes of Sterile vs Viral Pulmonary Inflammation in Male Mice. Endocrinology. 2020;161:bqaa201. https:\/\/doi.org\/10.1210\/endocr\/bqaa201.","journal-title":"Endocrinology"},{"key":"646_CR32","doi-asserted-by":"publisher","unstructured":"Adriaenssens A, Broichhagen J, Bray A de, Ast J, Hasib A, Jones B, et al. Hypothalamic and brainstem glucose-dependent insulinotropic polypeptide receptor neurons employ distinct mechanisms to affect feeding. JCI Insight 2023;8. https:\/\/doi.org\/10.1172\/jci.insight.164921.","DOI":"10.1172\/jci.insight.164921"},{"key":"646_CR33","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s00018-024-05507-6","volume":"81","author":"LN da Silva","year":"2024","unstructured":"da Silva LN, Cabaleiro A, Novoa E, Riobello C, Knerr PJ, He Y, et al. GLP-1 and GIP agonism has no direct actions in human hepatocytes or hepatic stellate cells. Cell Mol Life Sci. 2024;81:468. https:\/\/doi.org\/10.1007\/s00018-024-05507-6.","journal-title":"Cell Mol Life Sci"},{"key":"646_CR34","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/ejendo\/lvac004","volume":"188","author":"MS Hansen","year":"2023","unstructured":"Hansen MS, S\u00f8e K, Christensen LL, Fernandez-Guerra P, Hansen NW, Wyatt RA, et al. GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells. Eur J Endocrinol. 2023;188:144\u201357. https:\/\/doi.org\/10.1093\/ejendo\/lvac004.","journal-title":"Eur J Endocrinol"},{"key":"646_CR35","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio LL, Drucker DJ. Biology of Incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131\u201357. https:\/\/doi.org\/10.1053\/j.gastro.2007.03.054.","journal-title":"Gastroenterology"},{"key":"646_CR36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","volume":"20","author":"MA Nauck","year":"2018","unstructured":"Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 2018;20:5\u201321. https:\/\/doi.org\/10.1111\/dom.13129.","journal-title":"Diabetes Obes Metab"},{"key":"646_CR37","doi-asserted-by":"publisher","first-page":"e0289616","DOI":"10.1371\/journal.pone.0289616","volume":"18","author":"C Liao","year":"2023","unstructured":"Liao C, Liang X, Zhang X, Li Y. The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis. PLoS ONE. 2023;18:e0289616. https:\/\/doi.org\/10.1371\/journal.pone.0289616.","journal-title":"PLoS ONE"},{"key":"646_CR38","doi-asserted-by":"publisher","first-page":"113937","DOI":"10.1016\/j.intimp.2024.113937","volume":"147","author":"W Hu","year":"2025","unstructured":"Hu W, Gong W, Yang F, Cheng R, Zhang G, Gan L, et al. Dual GIP and GLP-1 receptor agonist tirzepatide alleviates hepatic steatosis and modulates gut microbiota and bile acid metabolism in diabetic mice. Int Immunopharmacol. 2025;147:113937. https:\/\/doi.org\/10.1016\/j.intimp.2024.113937.","journal-title":"Int Immunopharmacol"},{"key":"646_CR39","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jdiacomp.2012.12.005","volume":"27","author":"SL Samson","year":"2013","unstructured":"Samson SL, Bajaj M. Potential of incretin-based therapies for non-alcoholic fatty liver disease. J Diabetes Complications. 2013;27:401\u20136. https:\/\/doi.org\/10.1016\/j.jdiacomp.2012.12.005.","journal-title":"J Diabetes Complications"},{"issue":"147","key":"646_CR40","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.2139\/ssrn.4836442","volume":"7","author":"S Al-Naimi","year":"2024","unstructured":"Al-Naimi S, Turnock C. Glp-1 effects on adiponectin and il-6 expression in 3t3-l1 adipocytes: obesity and inflammation study. J Obes Nutr Disord. 2024;7(147):2577\u2013244. https:\/\/doi.org\/10.2139\/ssrn.4836442.","journal-title":"J Obes Nutr Disord"},{"key":"646_CR41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.bbrc.2008.08.052","volume":"376","author":"R Naitoh","year":"2008","unstructured":"Naitoh R, Miyawaki K, Harada N, Mizunoya W, Toyoda K, Fushiki T, et al. Inhibition of GIP signaling modulates adiponectin levels under high-fat diet in mice. Biochem Biophys Res Commun. 2008;376:21\u20135. https:\/\/doi.org\/10.1016\/j.bbrc.2008.08.052.","journal-title":"Biochem Biophys Res Commun"},{"key":"646_CR42","doi-asserted-by":"publisher","first-page":"170208","DOI":"10.1016\/j.peptides.2019.170208","volume":"125","author":"SK Thondam","year":"2020","unstructured":"Thondam SK, Cuthbertson DJ, Wilding JPH. The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD). Peptides. 2020;125:170208. https:\/\/doi.org\/10.1016\/j.peptides.2019.170208.","journal-title":"Peptides"},{"key":"646_CR43","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S2468-1253(22)00338-7","volume":"8","author":"G Targher","year":"2023","unstructured":"Targher G, Mantovani A, Byrne CD. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol. 2023;8:179\u201391. https:\/\/doi.org\/10.1016\/S2468-1253(22)00338-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"646_CR44","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.immuni.2020.08.004","volume":"53","author":"A Remmerie","year":"2020","unstructured":"Remmerie A, Martens L, Thon\u00e9 T, Castoldi A, Seurinck R, Pavie B, et al. Osteopontin expression identifies a subset of recruited macrophages distinct from kupffer cells in the fatty liver. Immunity. 2020;53:641-657.e14. https:\/\/doi.org\/10.1016\/j.immuni.2020.08.004.","journal-title":"Immunity"},{"key":"646_CR45","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.cell.2021.12.018","volume":"185","author":"M Guilliams","year":"2022","unstructured":"Guilliams M, Bonnardel J, Haest B, Vanderborght B, Wagner C, Remmerie A, et al. Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches. Cell. 2022;185:379-396.e38. https:\/\/doi.org\/10.1016\/j.cell.2021.12.018.","journal-title":"Cell"},{"key":"646_CR46","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"87","author":"JJ Holst","year":"2007","unstructured":"Holst JJ. The Physiology of Glucagon-like Peptide 1. Physiol Rev. 2007;87:1409\u201339. https:\/\/doi.org\/10.1152\/physrev.00034.2006.","journal-title":"Physiol Rev"},{"key":"646_CR47","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.2337\/db11-1274","volume":"61","author":"A Bertola","year":"2012","unstructured":"Bertola A, Ciucci T, Rousseau D, Bourlier V, Duffaut C, Bonnafous S, et al. Identification of adipose tissue dendritic cells correlated with obesity-associated insulin-resistance and inducing th17 responses in mice and patients. Diabetes. 2012;61:2238\u201347. https:\/\/doi.org\/10.2337\/db11-1274.","journal-title":"Diabetes"},{"issue":"11","key":"646_CR48","doi-asserted-by":"publisher","first-page":"597648","DOI":"10.3389\/fendo.2020.597648","volume":"14","author":"C Luci","year":"2020","unstructured":"Luci C, Bourinet M, Lecl\u00e8re PS, Anty R, Gual P. Chronic inflammation in non-alcoholic steatohepatitis: molecular mechanisms and therapeutic strategies. Front Endocrinol. 2020;14(11):597648. https:\/\/doi.org\/10.3389\/fendo.2020.597648.","journal-title":"Front Endocrinol"},{"key":"646_CR49","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.cmet.2019.08.018","volume":"30","author":"J Yuan","year":"2019","unstructured":"Yuan J, Chen C, Cui J, Lu J, Yan C, Wei X, et al. Fatty liver disease caused by high-alcohol-producing klebsiella pneumoniae. Cell Metab. 2019;30:675-688.e7. https:\/\/doi.org\/10.1016\/j.cmet.2019.08.018.","journal-title":"Cell Metab"},{"key":"646_CR50","doi-asserted-by":"publisher","unstructured":"Giuffr\u00e8 M, Campigotto M, Campisciano G, Comar M, Croc\u00e8 LS. A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature. American Journal of Physiology-Gastrointestinal and Liver Physiology 2020;318:G889\u2013906. https:\/\/doi.org\/10.1152\/ajpgi.00161.2019.","DOI":"10.1152\/ajpgi.00161.2019"},{"key":"646_CR51","doi-asserted-by":"publisher","first-page":"C263","DOI":"10.1152\/ajpcell.00295.2016","volume":"312","author":"P Gual","year":"2017","unstructured":"Gual P, Gilgenkrantz H, Lotersztajn S. Autophagy in chronic liver diseases: the two faces of Janus. Am J Physiol Cell Physiol. 2017;312:C263\u201373. https:\/\/doi.org\/10.1152\/ajpcell.00295.2016.","journal-title":"Am J Physiol Cell Physiol"},{"key":"646_CR52","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","volume":"68","author":"F Marra","year":"2018","unstructured":"Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018;68:280\u201395. https:\/\/doi.org\/10.1016\/j.jhep.2017.11.014.","journal-title":"J Hepatol"},{"key":"646_CR53","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/hep.32562","volume":"77","author":"A Ajoolabady","year":"2023","unstructured":"Ajoolabady A, Kaplowitz N, Lebeaupin C, Kroemer G, Kaufman RJ, Malhi H, et al. Endoplasmic reticulum stress in liver diseases. Hepatology. 2023;77:619. https:\/\/doi.org\/10.1002\/hep.32562.","journal-title":"Hepatology"},{"issue":"10","key":"646_CR54","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.3389\/fimmu.2019.01192","volume":"28","author":"C Luci","year":"2019","unstructured":"Luci C, Vieira E, Perchet T, Gual P, Golub R. Natural killer cells and type 1 innate lymphoid cells are new actors in non-alcoholic fatty liver disease. Fronti Immunol. 2019;28(10):1192. https:\/\/doi.org\/10.3389\/fimmu.2019.01192.","journal-title":"Fronti Immunol"},{"key":"646_CR55","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41575-019-0210-2","volume":"17","author":"S Sutti","year":"2020","unstructured":"Sutti S, Albano E. Adaptive immunity: an emerging player in the progression of NAFLD. Nat Rev Gastroenterol Hepatol. 2020;17:81\u201392. https:\/\/doi.org\/10.1038\/s41575-019-0210-2.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"646_CR56","doi-asserted-by":"publisher","first-page":"100962","DOI":"10.1016\/j.jhepr.2023.100962","volume":"6","author":"M Bourinet","year":"2024","unstructured":"Bourinet M, Anty R, Gual P, Luci C. Roles of innate lymphoid cells in metabolic and alcohol-associated liver diseases. JHEP Reports. 2024;6(2):100962. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100962.","journal-title":"JHEP Reports."},{"key":"646_CR57","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1053\/j.gastro.2008.03.002","volume":"134","author":"H Malhi","year":"2008","unstructured":"Malhi H, Gores GJ. Cellular and molecular mechanisms of liver injury. Gastroenterology. 2008;134:1641\u201354. https:\/\/doi.org\/10.1053\/j.gastro.2008.03.002.","journal-title":"Gastroenterology"},{"key":"646_CR58","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.cgh.2016.09.149","volume":"15","author":"M Balakrishnan","year":"2017","unstructured":"Balakrishnan M, Kanwal F, El-Serag HB, Thrift AP. Acculturation and nonalcoholic fatty liver disease risk among hispanics of mexican origin: findings from the national health and nutrition examination survey. Clin Gastroenterol Hepatol. 2017;15:310\u20132. https:\/\/doi.org\/10.1016\/j.cgh.2016.09.149.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"646_CR59","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.3390\/ijerph18105227","volume":"18","author":"O Juanola","year":"2021","unstructured":"Juanola O, Mart\u00ednez-L\u00f3pez S, Franc\u00e9s R, G\u00f3mez-Hurtado I. Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors. Int J Environ Res Public Health. 2021;18:5227. https:\/\/doi.org\/10.3390\/ijerph18105227.","journal-title":"Int J Environ Res Public Health"},{"key":"646_CR60","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jhep.2020.04.003","volume":"73","author":"QM Anstee","year":"2020","unstructured":"Anstee QM, Darlay R, Cockell S, Meroni M, Govaere O, Tiniakos D, et al. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort\u2606. J Hepatol. 2020;73:505\u201315. https:\/\/doi.org\/10.1016\/j.jhep.2020.04.003.","journal-title":"J Hepatol"},{"key":"646_CR61","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s12072-021-10200-y","volume":"15","author":"R Paternostro","year":"2021","unstructured":"Paternostro R, Staufer K, Traussnigg S, St\u00e4ttermayer A-F, Halilbasic E, Keritam O, et al. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease. Hepatol Int. 2021;15:922\u201333. https:\/\/doi.org\/10.1007\/s12072-021-10200-y.","journal-title":"Hepatol Int"},{"key":"646_CR62","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jhep.2014.02.030","volume":"61","author":"Y-L Liu","year":"2014","unstructured":"Liu Y-L, Patman GL, Leathart JBS, Piguet A-C, Burt AD, Dufour J-F, et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol. 2014;61:75\u201381. https:\/\/doi.org\/10.1016\/j.jhep.2014.02.030.","journal-title":"J Hepatol"},{"key":"646_CR63","doi-asserted-by":"publisher","unstructured":"Pingitore P, Romeo S. The role of PNPLA3 in health and disease. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2019;1864:900\u20136. https:\/\/doi.org\/10.1016\/j.bbalip.2018.06.018.","DOI":"10.1016\/j.bbalip.2018.06.018"},{"key":"646_CR64","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1038\/ncomms5309","volume":"5","author":"Y-L Liu","year":"2014","unstructured":"Liu Y-L, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JBS, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. 2014;5:4309. https:\/\/doi.org\/10.1038\/ncomms5309.","journal-title":"Nat Commun"},{"key":"646_CR65","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1186\/s12885-019-6173-4","volume":"19","author":"S Tang","year":"2019","unstructured":"Tang S, Zhang J, Mei T-T, Guo H-Q, Wei X-H, Zhang W-Y, et al. Association of TM6SF2 rs58542926 T\/C gene polymorphism with hepatocellular carcinoma: a meta-analysis. BMC Cancer. 2019;19:1128. https:\/\/doi.org\/10.1186\/s12885-019-6173-4.","journal-title":"BMC Cancer"},{"key":"646_CR66","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1053\/j.gastro.2016.01.037","volume":"150","author":"QM Anstee","year":"2016","unstructured":"Anstee QM, Seth D, Day CP. Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease. Gastroenterology. 2016;150:1728-1744.e7. https:\/\/doi.org\/10.1053\/j.gastro.2016.01.037.","journal-title":"Gastroenterology"},{"key":"646_CR67","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/liv.12120","volume":"33","author":"L Zhang","year":"2013","unstructured":"Zhang L, Yang M, Ren H, Hu H, Boden G, Li L, et al. GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK. Liver Int. 2013;33:794\u2013804. https:\/\/doi.org\/10.1111\/liv.12120.","journal-title":"Liver Int"},{"key":"646_CR68","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s10020-023-00721-7","volume":"29","author":"T Guo","year":"2023","unstructured":"Guo T, Yan W, Cui X, Liu N, Wei X, Sun Y, et al. Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK\/ACC signaling and inhibiting ferroptosis. Mol Med. 2023;29:132. https:\/\/doi.org\/10.1186\/s10020-023-00721-7.","journal-title":"Mol Med"},{"key":"646_CR69","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/hepr.12634","volume":"46","author":"W Tong","year":"2016","unstructured":"Tong W, Ju L, Qiu M, Xie Q, Chen Y, Shen W, et al. Liraglutide ameliorates non-alcoholic fatty liver disease by enhancing mitochondrial architecture and promoting autophagy through the SIRT1\/SIRT3\u2013FOXO3a pathway. Hepatol Res. 2016;46:933\u201343. https:\/\/doi.org\/10.1111\/hepr.12634.","journal-title":"Hepatol Res"},{"key":"646_CR70","doi-asserted-by":"publisher","unstructured":"Parlevliet ET, Wang Y, Geerling JJ, Elst JPS-V der, Picha K, O\u2019Neil K, et al. GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice. PLOS ONE 2012;7:e49152. https:\/\/doi.org\/10.1371\/journal.pone.0049152.","DOI":"10.1371\/journal.pone.0049152"},{"key":"646_CR71","doi-asserted-by":"publisher","first-page":"9324","DOI":"10.3390\/ijms24119324","volume":"24","author":"HA Lee","year":"2023","unstructured":"Lee HA, Kim HY. Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease. Int J Mol Sci. 2023;24:9324. https:\/\/doi.org\/10.3390\/ijms24119324.","journal-title":"Int J Mol Sci"},{"key":"646_CR72","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.metabol.2018.11.001","volume":"92","author":"KI Avgerinos","year":"2019","unstructured":"Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism. 2019;92:121\u201335. https:\/\/doi.org\/10.1016\/j.metabol.2018.11.001.","journal-title":"Metabolism"},{"key":"646_CR73","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1463-1326.2009.01176.x","volume":"12","author":"SA Polyzos","year":"2010","unstructured":"Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab. 2010;12:365\u201383. https:\/\/doi.org\/10.1111\/j.1463-1326.2009.01176.x.","journal-title":"Diabetes Obes Metab"},{"key":"646_CR74","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.jhep.2023.07.033","volume":"79","author":"PN Newsome","year":"2023","unstructured":"Newsome PN, Ambery P. Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver. J Hepatol. 2023;79:1557\u201365. https:\/\/doi.org\/10.1016\/j.jhep.2023.07.033.","journal-title":"J Hepatol"},{"key":"646_CR75","doi-asserted-by":"publisher","first-page":"111675","DOI":"10.1016\/j.diabres.2024.111675","volume":"16","author":"B Brouwers","year":"2024","unstructured":"Brouwers B, Rao G, Tang Y, Rodr\u00edguez \u00c1, Glass LC, Hartman ML. Incretin-based investigational therapies for the treatment of MASLD\/MASH. Diabetes Res Clinic Pract. 2024;16:111675. https:\/\/doi.org\/10.1016\/j.diabres.2024.111675.","journal-title":"Diabetes Res Clinic Pract"},{"key":"646_CR76","doi-asserted-by":"publisher","first-page":"549","DOI":"10.4239\/wjd.v14.i5.549","volume":"14","author":"IDN Wibawa","year":"2023","unstructured":"Wibawa IDN, Mariadi IK, Somayana G, Krisnawardani Kumbara CIY, Sindhughosa DA. Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management. World J Diabetes. 2023;14:549\u201359. https:\/\/doi.org\/10.4239\/wjd.v14.i5.549.","journal-title":"World J Diabetes"},{"key":"646_CR77","doi-asserted-by":"publisher","first-page":"731","DOI":"10.4254\/wjh.v16.i5.731","volume":"16","author":"C Xie","year":"2024","unstructured":"Xie C, Alkhouri N, Elfeki MA. Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges. World J Hepatol. 2024;16:731\u201350. https:\/\/doi.org\/10.4254\/wjh.v16.i5.731.","journal-title":"World J Hepatol"},{"key":"646_CR78","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1007\/s00125-023-05966-9","volume":"66","author":"CR Andreasen","year":"2023","unstructured":"Andreasen CR, Andersen A, Vilsb\u00f8ll T. The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease. Diabetologia. 2023;66:1846\u201358. https:\/\/doi.org\/10.1007\/s00125-023-05966-9.","journal-title":"Diabetologia"},{"key":"646_CR79","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. The Lancet. 2016;387:679\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(15)00803-X.","journal-title":"The Lancet"},{"key":"646_CR80","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384:1113\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2028395.","journal-title":"N Engl J Med"},{"key":"646_CR81","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kj\u00e6r MS, Krarup N, et al. Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:511\u201322. https:\/\/doi.org\/10.1016\/S2468-1253(23)00068-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11\u201312","key":"646_CR82","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1111\/apt.18331","volume":"60","author":"PN Newsome","year":"2024","unstructured":"Newsome PN, Sanyal AJ, Engebretsen KA, Kliers I, \u00d8stergaard L, Vanni D, Bugianesi E, Rinella ME, Roden M, Ratziu V. Semaglutide 2.4 mg in participants with metabolic dysfunction-associated Steatohepatitis: baseline characteristics and Design of the Phase 3 ESSENCE trial. Aliment Pharmacol Ther. 2024;60(11\u201312):1525\u201333. https:\/\/doi.org\/10.1111\/apt.18331.","journal-title":"Aliment Pharmacol Ther"},{"key":"646_CR83","unstructured":"Huang R, Ji F, Jiang Y, Li S, Su M, Zhong Y, et al. The Liver Meeting: Late Breaking Abstract Supplement 2024."},{"key":"646_CR84","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391:299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943.","journal-title":"N Engl J Med"},{"key":"646_CR85","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, et al. A Phase 2 randomized trial of survodutide in mash and fibrosis. N Engl J Med. 2024;391:311\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2401755.","journal-title":"N Engl J Med"},{"key":"646_CR86","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553\u201364. https:\/\/doi.org\/10.1111\/dom.14725.","journal-title":"Diabetes Obes Metab"},{"key":"646_CR87","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1001\/jama.2023.7592","volume":"329","author":"DS Ludwig","year":"2023","unstructured":"Ludwig DS, Holst JJ. Childhood obesity at the crossroads of science and social justice. JAMA. 2023;329:1909\u201310. https:\/\/doi.org\/10.1001\/jama.2023.7592.","journal-title":"JAMA"},{"key":"646_CR88","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1097\/HEP.0000000000000263","volume":"77","author":"L Castera","year":"2023","unstructured":"Castera L, Cusi K. Diabetes and cirrhosis: current concepts on diagnosis and management. Hepatology. 2023;77:2128. https:\/\/doi.org\/10.1097\/HEP.0000000000000263.","journal-title":"Hepatology"},{"key":"646_CR89","doi-asserted-by":"publisher","first-page":"e3157","DOI":"10.1002\/dmrr.3157","volume":"35","author":"WG Lee","year":"2019","unstructured":"Lee WG, Wells CI, McCall JL, Murphy R, Plank LD. Prevalence of diabetes in liver cirrhosis: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2019;35:e3157. https:\/\/doi.org\/10.1002\/dmrr.3157.","journal-title":"Diabetes Metab Res Rev"},{"key":"646_CR90","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71:793\u2013801. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.021.","journal-title":"J Hepatol"},{"key":"646_CR91","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/liv.13115","volume":"36","author":"L Elkrief","year":"2016","unstructured":"Elkrief L, Rautou P-E, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver Int. 2016;36:936\u201348. https:\/\/doi.org\/10.1111\/liv.13115.","journal-title":"Liver Int"},{"key":"646_CR92","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1053\/j.gastro.2023.04.025","volume":"165","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Wilson LA, Behling C, Kleiner DE, Kowdley KV, Dasarathy S, et al. Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study. Gastroenterology. 2023;165:463-472.e5. https:\/\/doi.org\/10.1053\/j.gastro.2023.04.025.","journal-title":"Gastroenterology"},{"key":"646_CR93","doi-asserted-by":"publisher","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2022;65:1925\u201366. https:\/\/doi.org\/10.1007\/s00125-022-05787-2.","DOI":"10.1007\/s00125-022-05787-2"},{"key":"646_CR94","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1097\/HEP.0000000000001015","volume":"81","author":"DQ Huang","year":"2025","unstructured":"Huang DQ, Wilson LA, Behling C, Amangurbanova M, Kleiner DE, Kowdley KV, et al. Liver stiffness progression in biopsy-proven metabolic dysfunction\u2013associated steatotic disease among people with diabetes versus people without diabetes: A prospective multicenter study. Hepatology. 2025;81:1553. https:\/\/doi.org\/10.1097\/HEP.0000000000001015.","journal-title":"Hepatology"},{"key":"646_CR95","doi-asserted-by":"publisher","first-page":"101272","DOI":"10.1016\/j.diabet.2021.101272","volume":"47","author":"J Boursier","year":"2021","unstructured":"Boursier J, Anty R, Carette C, Cariou B, Castera L, Caussy C, et al. Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement. Diabetes Metab. 2021;47:101272. https:\/\/doi.org\/10.1016\/j.diabet.2021.101272.","journal-title":"Diabetes Metab"},{"key":"646_CR96","doi-asserted-by":"publisher","unstructured":"Tacke F, Horn P, Wong VW-S, Ratziu V, Bugianesi E, Francque S, et al. EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Journal of Hepatology 2024;81:492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031.","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"646_CR97","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jhep.2016.04.005","volume":"65","author":"SM Francque","year":"2016","unstructured":"Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. J Hepatol. 2016;65:425\u201343. https:\/\/doi.org\/10.1016\/j.jhep.2016.04.005.","journal-title":"J Hepatol"},{"key":"646_CR98","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/XCE.0000000000000197","volume":"9","author":"G Rodriguez-Araujo","year":"2020","unstructured":"Rodriguez-Araujo G. Nonalcoholic fatty liver disease: implications for endocrinologists and cardiologists. Cardiovasc Endocrinol Metab. 2020;9:96\u2013100. https:\/\/doi.org\/10.1097\/XCE.0000000000000197.","journal-title":"Cardiovasc Endocrinol Metab"},{"issue":"11","key":"646_CR99","doi-asserted-by":"publisher","first-page":"622589","DOI":"10.3389\/fendo.2020.622589","volume":"16","author":"Y Dai","year":"2021","unstructured":"Dai Y, He H, Li S, Yang L, Wang X, Liu Z, An Z. Comparison of the efficacy of glucagon-like peptide-1 receptor agonists in patients with metabolic associated fatty liver disease: updated systematic review and meta-analysis. Front Endocrinol. 2021;16(11):622589. https:\/\/doi.org\/10.3389\/fendo.2020.622589.","journal-title":"Front Endocrinol"},{"key":"646_CR100","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Gaal LFV, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"key":"646_CR101","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med"},{"key":"646_CR102","doi-asserted-by":"publisher","unstructured":"Aronne LJ, Horn DB, Roux CW le, Ho W, Falcon BL, Valderas EG, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England J Med 2025;0. https:\/\/doi.org\/10.1056\/NEJMoa2416394.","DOI":"10.1056\/NEJMoa2416394"},{"key":"646_CR103","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3390\/metabo13030330","volume":"13","author":"MA Farrugia","year":"2023","unstructured":"Farrugia MA, Le Garf S, Chierici A, Piche T, Gual P, Iannelli A, et al. Therapeutic physical exercise programs in the context of nash cirrhosis and liver transplantation: a systematic review. Metabolites. 2023;13:330. https:\/\/doi.org\/10.3390\/metabo13030330.","journal-title":"Metabolites"},{"key":"646_CR104","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A Phase 3, randomized, controlled trial of resmetirom in nash with liver fibrosis. N Engl J Med. 2024;390:497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000.","journal-title":"N Engl J Med"},{"key":"646_CR105","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.cgh.2024.07.003","volume":"22","author":"M Noureddin","year":"2024","unstructured":"Noureddin M, Charlton MR, Harrison SA, Bansal MB, Alkhouri N, Loomba R, et al. Expert panel recommendations: practical clinical applications for initiating and monitoring resmetirom in patients with mash\/nash and moderate to noncirrhotic advanced fibrosis. Clin Gastroenterol Hepatol. 2024;22:2367\u201377. https:\/\/doi.org\/10.1016\/j.cgh.2024.07.003.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"646_CR106","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","volume":"81","author":"VL Chen","year":"2025","unstructured":"Chen VL, Morgan TR, Rotman Y, Patton HM, Cusi K, Kanwal F, et al. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance. Hepatology. 2025;81:312. https:\/\/doi.org\/10.1097\/HEP.0000000000001112.","journal-title":"Hepatology"},{"key":"646_CR107","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/d41573-024-00051-1","volume":"23","author":"K Kingwell","year":"2024","unstructured":"Kingwell K. NASH field celebrates \u2018hurrah moment\u2019 with a first FDA drug approval for the liver disease. Nat Rev Drug Discovery. 2024;23:235\u20137. https:\/\/doi.org\/10.1038\/d41573-024-00051-1.","journal-title":"Nat Rev Drug Discovery"},{"key":"646_CR108","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","volume":"385","author":"SM Francque","year":"2021","unstructured":"Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, et al. A Randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH. N Engl J Med. 2021;385:1547\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2036205.","journal-title":"N Engl J Med"},{"issue":"10","key":"646_CR109","doi-asserted-by":"publisher","first-page":"440125","DOI":"10.3389\/fphys.2019.00419","volume":"17","author":"C Tezze","year":"2019","unstructured":"Tezze C, Romanello V, Sandri M. FGF21 as Modulator of Metabolism in Health and Disease. Front Physiol. 2019;17(10):440125. https:\/\/doi.org\/10.3389\/fphys.2019.00419.","journal-title":"Front Physiol"},{"key":"646_CR110","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","volume":"389","author":"R Loomba","year":"2023","unstructured":"Loomba R, Sanyal AJ, Kowdley KV, Bhatt DL, Alkhouri N, Frias JP, et al. Randomized, controlled trial of the FGF21 Analogue Pegozafermin in NASH. N Engl J Med. 2023;389:998\u20131008. https:\/\/doi.org\/10.1056\/NEJMoa2304286.","journal-title":"N Engl J Med"},{"key":"646_CR111","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","volume":"8","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Frias JP, Neff G, Abrams GA, Lucas KJ, Sanchez W, et al. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2023;8:1080\u201393. https:\/\/doi.org\/10.1016\/S2468-1253(23)00272-8.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"646_CR112","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","volume":"159","author":"G Lassailly","year":"2020","unstructured":"Lassailly G, Caiazzo R, Ntandja-Wandji L-C, Gnemmi V, Baud G, Verkindt H, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology. 2020;159:1290-1301.e5. https:\/\/doi.org\/10.1053\/j.gastro.2020.06.006.","journal-title":"Gastroenterology"},{"key":"646_CR113","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/hep.32358","volume":"76","author":"R Pais","year":"2022","unstructured":"Pais R, Aron-Wisnewsky J, Bedossa P, Ponnaiah M, Oppert J-M, Siksik J-M, et al. Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery. Hepatology. 2022;76:456. https:\/\/doi.org\/10.1002\/hep.32358.","journal-title":"Hepatology"},{"key":"646_CR114","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3350\/cmh.2023.0384","volume":"30","author":"J Hwang","year":"2024","unstructured":"Hwang J, Hwang H, Shin H, Kim BH, Kang SH, Yoo J-J, et al. Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis. Clin Mol Hepatol. 2024;30:561\u201376. https:\/\/doi.org\/10.3350\/cmh.2023.0384.","journal-title":"Clin Mol Hepatol"},{"key":"646_CR115","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s11695-023-06484-8","volume":"33","author":"AB Jensen","year":"2023","unstructured":"Jensen AB, Renstr\u00f6m F, Acz\u00e9l S, Folie P, Biraima-Steinemann M, Beuschlein F, et al. Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study. Obes Surg. 2023;33:1017\u201325. https:\/\/doi.org\/10.1007\/s11695-023-06484-8.","journal-title":"Obes Surg"},{"key":"646_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156101","volume":"163","author":"M Tampaki","year":"2025","unstructured":"Tampaki M, Tsochatzis E, Lekakis V, Cholongitas E. Prevalence, characteristics and outcomes of patients with metabolic and alcohol related\/associated liver disease (MetALD): a systematic review and meta-analysis. Metabolism. 2025;163: 156101. https:\/\/doi.org\/10.1016\/j.metabol.2024.156101.","journal-title":"Metabolism"},{"key":"646_CR117","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1097\/HEP.0000000000000664","volume":"79","author":"C Lee","year":"2024","unstructured":"Lee C, Yoon EL, Kim M, Kang B-K, Cho S, Nah E-H, et al. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings. Hepatology. 2024;79:1393. https:\/\/doi.org\/10.1097\/HEP.0000000000000664.","journal-title":"Hepatology"},{"key":"646_CR118","doi-asserted-by":"publisher","first-page":"155800","DOI":"10.1016\/j.metabol.2024.155800","volume":"153","author":"HJ Choe","year":"2024","unstructured":"Choe HJ, Moon JH, Kim W, Koo BK, Cho NH. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up. Metabolism. 2024;153:155800. https:\/\/doi.org\/10.1016\/j.metabol.2024.155800.","journal-title":"Metabolism"},{"key":"646_CR119","doi-asserted-by":"publisher","first-page":"101250","DOI":"10.1016\/j.jhepr.2024.101250","volume":"7","author":"J Gratac\u00f3s-Gin\u00e8s","year":"2025","unstructured":"Gratac\u00f3s-Gin\u00e8s J, Ari\u00f1o S, Sancho-Bru P, Bataller R, Pose E. MetALD: Clinical aspects, pathophysiology and treatment. JHEP Reports. 2025;7:101250. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101250.","journal-title":"JHEP Reports"},{"key":"646_CR120","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/adb.12295","volume":"21","author":"D Vall\u00f6f","year":"2016","unstructured":"Vall\u00f6f D, Maccioni P, Colombo G, Mandrapa M, J\u00f6rnulf JW, Egecioglu E, et al. The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addict Biol. 2016;21:422\u201337. https:\/\/doi.org\/10.1111\/adb.12295.","journal-title":"Addict Biol"},{"key":"646_CR121","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1097\/HEP.0000000000000935","volume":"80","author":"GW Marek","year":"2024","unstructured":"Marek GW, Malhi H. MetALD: Does it require a different therapeutic option? Hepatology. 2024;80:1424. https:\/\/doi.org\/10.1097\/HEP.0000000000000935.","journal-title":"Hepatology"},{"key":"646_CR122","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/apt.17925","volume":"59","author":"MI Elsaid","year":"2024","unstructured":"Elsaid MI, Li N, Firkins SA, Rustgi VK, Paskett ED, Acharya C, et al. Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes. Aliment Pharmacol Ther. 2024;59:1096\u2013110. https:\/\/doi.org\/10.1111\/apt.17925.","journal-title":"Aliment Pharmacol Ther"},{"key":"646_CR123","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1038\/s41598-025-89408-z","volume":"15","author":"B Havranek","year":"2025","unstructured":"Havranek B, Loh R, Torre B, Redfield R, Halegoua-DeMarzio D. Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes. Sci Rep. 2025;15:4947. https:\/\/doi.org\/10.1038\/s41598-025-89408-z.","journal-title":"Sci Rep"},{"key":"646_CR124","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/gutjnl-2024-334591","volume":"74","author":"C Celsa","year":"2025","unstructured":"Celsa C, Pennisi G, Tulone A, Ciancimino G, Vaccaro M, Infantino G, et al. Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies. Gut. 2025;74:815\u201324. https:\/\/doi.org\/10.1136\/gutjnl-2024-334591.","journal-title":"Gut"},{"key":"646_CR125","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9:653\u201362. https:\/\/doi.org\/10.1016\/S2213-8587(21)00203-5.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"646_CR126","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.3390\/microorganisms10102061","volume":"10","author":"N Abdalqadir","year":"2022","unstructured":"Abdalqadir N, Adeli K. GLP-1 and GLP-2 orchestrate intestine integrity, gut microbiota, and immune system crosstalk. Microorganisms. 2022;10:2061. https:\/\/doi.org\/10.3390\/microorganisms10102061.","journal-title":"Microorganisms"},{"key":"646_CR127","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1053\/j.gastro.2005.10.004","volume":"130","author":"JJ Meier","year":"2006","unstructured":"Meier JJ, Nauck MA, Pott A, Heinze K, Goetze O, Bulut K, et al. Glucagon-Like Peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology. 2006;130:44\u201354. https:\/\/doi.org\/10.1053\/j.gastro.2005.10.004.","journal-title":"Gastroenterology"},{"issue":"8","key":"646_CR128","doi-asserted-by":"publisher","first-page":"e136907","DOI":"10.1172\/jci.insight.136907","volume":"5","author":"S Fuchs","year":"2020","unstructured":"Fuchs S, Yusta B, Baggio LL, Varin EM, Matthews D, Drucker DJ. Loss of Glp2r signaling activates hepatic stellate cells and exacerbates diet-induced steatohepatitis in mice. JCI Insight. 2020;5(8):e136907. https:\/\/doi.org\/10.1172\/jci.insight.136907.","journal-title":"JCI Insight"},{"key":"646_CR129","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1002\/hep.32235","volume":"75","author":"ER Kim","year":"2022","unstructured":"Kim ER, Park JS, Kim JH, Oh JY, Oh IJ, Choi DH, et al. A GLP-1\/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome. Hepatology. 2022;75:1523. https:\/\/doi.org\/10.1002\/hep.32235.","journal-title":"Hepatology"},{"key":"646_CR130","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","volume":"2","author":"ML Boland","year":"2020","unstructured":"Boland ML, Laker RC, Mather K, Nawrocki A, Oldham S, Boland BB, et al. Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis. Nat Metab. 2020;2:413\u201331. https:\/\/doi.org\/10.1038\/s42255-020-0209-6.","journal-title":"Nat Metab"},{"key":"646_CR131","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/j.cgh.2024.04.017","volume":"22","author":"SS Shankar","year":"2024","unstructured":"Shankar SS, Daniels SJ, Robertson D, Sarv J, S\u00e1nchez J, Carter D, et al. Safety and efficacy of novel incretin Co-agonist cotadutide in biopsy-proven noncirrhotic MASH With Fibrosis. Clin Gastroenterol Hepatol. 2024;22:1847-1857.e11. https:\/\/doi.org\/10.1016\/j.cgh.2024.04.017.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"646_CR132","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","volume":"30","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30:2037\u201348. https:\/\/doi.org\/10.1038\/s41591-024-03018-2.","journal-title":"Nat Med"},{"key":"646_CR133","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/fcp.13024","volume":"38","author":"PH Reis-Barbosa","year":"2024","unstructured":"Reis-Barbosa PH, Mandarim-de-Lacerda CA. Sodium-glucose cotransporter-2 inhibitor (SGLT2i) plus glucagon-like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase-4 inhibitor combination in treating obese mice metabolic dysfunction-associated steatotic liver disease (MASLD). Fundam Clin Pharmacol. 2024;38:1059\u201368. https:\/\/doi.org\/10.1111\/fcp.13024.","journal-title":"Fundam Clin Pharmacol"},{"key":"646_CR134","doi-asserted-by":"publisher","first-page":"e0302155","DOI":"10.1371\/journal.pone.0302155","volume":"19","author":"Y-H Lin","year":"2024","unstructured":"Lin Y-H, Zhang Z-J, Zhong J-Q, Wang Z-Y, Peng Y-T, Lin Y-M, et al. Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial. PLOS ONE. 2024;19:e0302155. https:\/\/doi.org\/10.1371\/journal.pone.0302155.","journal-title":"PLOS ONE"},{"key":"646_CR135","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cgh.2024.02.022","volume":"23","author":"SA Harrison","year":"2025","unstructured":"Harrison SA, Frias JP, Lucas KJ, Reiss G, Neff G, Bollepalli S, et al. Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH\/MASH and Type 2 Diabetes in a Randomized Phase 2 Study. Clin Gastroenterol Hepatol. 2025;23:103\u201313. https:\/\/doi.org\/10.1016\/j.cgh.2024.02.022.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"646_CR136","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","volume":"82","author":"SA Harrison","year":"2025","unstructured":"Harrison SA, Browne SK, Suschak JJ, Tomah S, Gutierrez JA, Yang J, et al. Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. J Hepatol. 2025;82:7\u201317. https:\/\/doi.org\/10.1016\/j.jhep.2024.07.006.","journal-title":"J Hepatol"},{"key":"646_CR137","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1056\/NEJMc2402341","volume":"391","author":"E Fabbrini","year":"2024","unstructured":"Fabbrini E, Rady B, Koshkina A, Jeon JY, Ayyar VS, Gargano C, et al. Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLD. N Engl J Med. 2024;391:475\u20136. https:\/\/doi.org\/10.1056\/NEJMc2402341.","journal-title":"N Engl J Med"},{"key":"646_CR138","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","volume":"394","author":"R Pratley","year":"2019","unstructured":"Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. The Lancet. 2019;394:39\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(19)31271-1.","journal-title":"The Lancet"},{"key":"646_CR139","doi-asserted-by":"publisher","first-page":"110605","DOI":"10.1016\/j.diabres.2023.110605","volume":"198","author":"A Li","year":"2023","unstructured":"Li A, Su X, Hu S, Wang Y. Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2023;198:110605. https:\/\/doi.org\/10.1016\/j.diabres.2023.110605.","journal-title":"Diabetes Res Clin Pract"},{"key":"646_CR140","doi-asserted-by":"publisher","unstructured":"Knop FK, Aroda VR, Vale RD do, Holst-Hansen T, Laursen PN, Rosenstock J, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2023;402:705\u201319. https:\/\/doi.org\/10.1016\/S0140-6736(23)01185-6.","DOI":"10.1016\/S0140-6736(23)01185-6"},{"key":"646_CR141","doi-asserted-by":"publisher","unstructured":"McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. New England Journal of Medicine n.d.;0. https:\/\/doi.org\/10.1056\/NEJMoa2501006.","DOI":"10.1056\/NEJMoa2501006"}],"container-title":["Current Obesity Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-025-00646-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13679-025-00646-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-025-00646-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T11:02:25Z","timestamp":1750935745000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13679-025-00646-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":141,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["646"],"URL":"https:\/\/doi.org\/10.1007\/s13679-025-00646-8","relation":{},"ISSN":["2162-4968"],"issn-type":[{"value":"2162-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"assertion":[{"value":"9 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}},{"value":"This article does not contain any studies with\u00a0human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"56"}}